VolitionRX Ltd Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
57.2%projected annual EPS growth
Analyst Coverage
4analysts covering
FY EPS (est.)
-$2.00next fiscal year
Monitoring Framework
Key Performance Indicators
Quarterly Revenue Growth Quarterly30,000.0%Target: Maintain triple-digit year-over-year growth as commercialization scales
Annual Revenue Annually1.7MTarget: Accelerate commercial revenue across veterinary and human diagnostic pillars
Operating Cash Burn Reduction Annually24.0Target: Further reduce operating expenses and cash burn in 2026
Watch Items
- Going Concern and Liquidity RiskTrigger: Cash balance falling below $3 million without immediate non-dilutive or equity fundingAction: Monitor ATM equity sales, convertible note issuances, and milestone payments to extend runway
- Nu.Q Vet Feline Lymphoma Manuscript PublicationTrigger: Official publication of the clinical manuscriptAction: Secure and collect the anticipated $5 million milestone payment upon publication
- Sysmex Collaboration ProgressTrigger: Completion of the optimization phase of the Nu.Q NETs H3.1 assay on Sysmex platformsAction: Track progress toward commercialization and potential out-licensing terms
- NYSE American Listing ComplianceTrigger: Compliance plan deadline of August 6, 2027Action: Monitor execution of the accepted compliance plan to maintain listing status
Research as of 20 Jun 2026